Abstract
Background
Care of patients with locally recurrent rectal cancer (LRRC) requires careful patient selection. While curative resection offers survival benefits, significant trade-offs exist for the patient. Knowledge of patient-reported outcomes will help inform treatment decisions.
Methods
Quality of life (QOL) and pain were prospectively assessed in 105 patients treated for LRRC at a single institution, using the validated Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Brief Pain Inventory (BPI) questionnaires. In 54 patients enrolled and followed from diagnosis of LRRC, relationship between pretreatment pain, QOL, and overall survival (OS) were examined.
Results
Patients underwent curative surgical resection (C, 59%), noncurative surgery (NC, 12%) or nonsurgical treatment (NS, 28%). Median OS was 7.1, 1.4, and 1.9 years, respectively (C versus NC: p < 0.001; C versus NS: p = 0.006; NC versus NS: p = 0.261). Physical well-being QOL differed over time (p = 0.042), with greatest difference between C and NC surgery patients (p = 0.049). The remaining QOL domain scores and pain scores demonstrated no significant time or treatment effect. For the 54 patients assessed from diagnosis, median OS was independently predicted by treatment group (C, NC, NS: 4.3, 1.7, versus 2.4 years; p < 0.001) and pretreatment pain intensity (score ≤ 4 versus > 4: 3.8 versus 2.0 years; p = 0.001).
Conclusion
Curative surgery offered prolonged survival, but significant pain exists among long-term survivors and should be a focus of survivorship care. Noncurative surgery did not offer apparent advantages over nonsurgical palliation. Patient’s pretreatment pain has prognostic value, and should be assessed, treated, and considered in treatment decisions.
Similar content being viewed by others
References
Heald RJ. The ‘Holy Plane’ of rectal surgery. J R Soc Med. 1988;81:503–8.
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.
Nielsen MB, Laurberg S, Holm T. Current management of locally recurrent rectal cancer. Colorectal Dis. 2009. doi:10.1111/j.1463-1318.2009.02167.x.
Silberfein EJ, Kattepogu KM, Hu CY, et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010;17L:2863–9.
Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol. 2001;27:349–53.
de Chaisemartin C, Penna C, Goere D, et al. Presentation and prognosis of local recurrence after total mesorectal excision. Color Dis. 2009;11:60–6.
Bakx R, Visser O, Josso J, Meijer S, Slors JF, van Lanschot JJ. Management of recurrent rectal cancer: a population based study in greater Amsterdam. World J Gastroenterol. 2008;14:6018–23.
Palmer G, Martling A, Cedermark B, Holm T. A population-based study on the management and outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2007;14:447–54.
Bedrosian I, Giacco G, Pederson L, et al. Outcome after curative resection for locally recurrent rectal cancer. Dis Colon Rectum. 2006;49:175–82.
Rodriguez-Bigas MA, Chang GJ, Skibber JM. Barriers to rehabilitation of colorectal cancer patients. J Surg Oncol. 2007;95:400–8.
Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.
Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res. 1999;8:181–95.
Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592–6.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–38.
Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19.
Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–21.
Cleeland CS. The brief pain inventory user guide. Houston, TX: The University of Texas M. D. Anderson Cancer Center; 2009.
FACT-C scoring sheet. cited; Available from: www.facit.org. Last accessed April 1, 2010.
Hahnloser D, Nelson H, Gunderson LL, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg. 2003;237:502–8.
Miner TJ, Jaques DP, Paty PB, Guillem JG, Wong WD. Symptom control in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2003;10:72–9.
Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. Dis Colon Rectum. 2005;48:929–37.
Caricato M, Borzomati D, Ausania F, Valeri S, Rosignoli A, Coppola R. Prognostic factors after surgery for locally recurrent rectal cancer: an overview. Eur J Surg Oncol. 2006;32:126–32.
Hansen MH, Balteskard L, Dorum LM, Eriksen MT, Vonen B. Locally recurrent rectal cancer in Norway. Br J Surg. 2009;96:1176–82.
Kusters M, Dresen RC, Martijn H, et al. Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75:1444–9.
Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum. 2000;43:1695–701; discussion 701–3.
Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865–71.
Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27:3547–56.
Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26:2544–9.
Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol. 2008;108:100–5.
Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer. 2002;38:1351–7.
Sullivan PW, Nelson JB, Mulani PM, Sleep D. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2006;15:1297–306.
Movsas B, Moughan J, Sarna L, et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009;27:5816–22.
Esnaola NF, Cantor SB, Johnson ML, et al. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol. 2002;20:4361–7.
Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8:189–98.
Acknowledgment
Authors are grateful for the assistance in data analysis provided by Wei Qiao from the Department of Biostatics, The University of Texas MD Anderson Cancer Center, Houston TX.
Author information
Authors and Affiliations
Corresponding author
Additional information
Accepted for oral presentation at the 63rd Annual Meeting of the Society of Surgical Oncology, St. Louis, MO, 2010.
Rights and permissions
About this article
Cite this article
You, Y.N., Habiba, H., Chang, G.J. et al. Prognostic Value of Quality of Life and Pain in Patients with Locally Recurrent Rectal Cancer. Ann Surg Oncol 18, 989–996 (2011). https://doi.org/10.1245/s10434-010-1218-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-010-1218-6